放化疗联合治疗局部晚期非小细胞肺癌临床疗效观察  

Clinical observation of chemoradiotherapy in the treatment of locally advanced non-small lung cancer

作　　者：房丽[1] 王红阳[2] 王玲玲[1] 马守东[1] 孙建光[2] 郑海荣[2] 丁俊兰[2] 

机构地区：[1]唐山市人民医院放化科,河北唐山063000 [2]河北联合大学医学部,河北唐山063000

出　　处：《临床肺科杂志》2014年第7期1291-1294,共4页Journal of Clinical Pulmonary Medicine

基　　金：河北省卫生厅医学适用技术跟踪项目(No GL-2010-32)

摘　　要：目的：探讨放疗同期紫杉醇联合卡铂方案与序贯放化疗治疗局部晚期非小细胞肺癌（ NSCLC）疗效及毒副反应。方法将60例局部晚期NSCLC患者随机分为放化同步组（同步组）和放化疗组（序贯组）各30例；两组均行适形放疗，化疗均为PC方案，同步组每周一次；序贯组每3周一次，化疗2周期后再行放疗。观察两组治疗近期有效率、生存率及急性毒副反应。结果两组均完成放化疗，同步组总有效率86.67%，序贯组63．33%（P〈0．05）；3~4级骨髓抑制发生率同步组为30．0%，序贯组为23．3%；同步组和序贯组3~4级放射性肺炎发生率分别为13．4%和6．7%（P〈0．05）；均可耐受。结论同步放化疗能够显著提高局部晚期NSCLC生存率，急性毒副反应均可耐受。Objective To evaluate the curative effect and side effect of RT combined with PC concurrent chemotherapy in the treatment of locally advanced NSCLC. Methods 60 patients with locally advanced non-small cell lung cancer were divided into two groups and treated with radiotherapy, 30 patients in the concurrent group and 30 in the sequential group. Response rate and adverse reactions were evaluated. Results The overall response rate （ CR＋PR） was 86. 67% and 63. 33% respectively in the concurrent group and the sequential group （ P〈0. 05 ） . The incidence of bone marrow depression was 30% and 23. 3% and the occurrence of radiation pneumonia was 13. 4% and 6. 7% respectively in the concurrent group and the sequential group. Conclusion Concurrent chemora-diotherapy is well tolerated and can improve response rate in most patients with locally advanced non-small cell lung cancer.

关 键 词：局部晚期非小细胞肺癌 同步放化疗 紫杉醇 卡铂 

分 类 号：R734.2[医药卫生—肿瘤]